title: Development of antiviral treatment strategies in murine models.
abstract: Murine models with type C murine leukemia viruses have been used to develop major new prophylactic and therapeutic strategies in vaccination, drug therapy of acute virus exposure and chronic viremia, combination therapy, prevention of maternal transmission, and therapy targeted to the central nervous system. Transgenic mice expressing either the whole human immunodeficiency virus type 1 (HIV-1) provirus or subgenomic sequences allow the in vivo analysis of selected HIV-1 functions. The full replicative cycle of HIV-1 can be studied in human/mouse chimerae which were created by transplanting human hematolymphoid cells into SCID mice. The chimeric SCID mouse models have been used successfully to evaluate anti-HIV-1 drugs. The role of the various murine retrovirus systems in the development of anti-HIV-1 and anti-AIDS therapies is summarized.
authors.affiliation: Laboratory of Viral Pathogenesis, Dana-Farber Cancer Institute, Boston, MA.
authors.forename: R M
authors.initials: RM
authors.lastname: Ruprecht
authors.forename: J A
authors.initials: JA
authors.lastname: Koch
authors.forename: P L
authors.initials: PL
authors.lastname: Sharma
authors.forename: R S
authors.initials: RS
authors.lastname: Armany
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004357:Drug Synergism; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D016898:Interferon-alpha / Q000627:therapeutic use; D009052:Leukemia Virus, Murine / Q000187:drug effects*; D051379:Mice; D016513:Mice, SCID; D008822:Mice, Transgenic; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D015215:Zidovudine